Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GRDN
stocks logo

GRDN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast GRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDN is 34.50 USD with a low forecast of 34.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast GRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDN is 34.50 USD with a low forecast of 34.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 29.320
sliders
Low
34.00
Averages
34.50
High
35.00
Current: 29.320
sliders
Low
34.00
Averages
34.50
High
35.00
Truist
Buy
maintain
$30 -> $34
2025-11-14
Reason
Truist
Price Target
$30 -> $34
2025-11-14
maintain
Buy
Reason
Truist raised the firm's price target on Guardian Pharmacy to $34 from $30 and keeps a Buy rating on the shares. The firm has updated its model to reflect the company's Q3 earnings beat and guidance raise, the analyst tells investors in a research note. Truist is positive on Guardian's leading positioning in the fragmented long-term care pharmacy industry which carries "brisk overarching secular demand drivers".
Oppenheimer
Oppenheimer
Outperform
maintain
$30 -> $35
2025-11-11
Reason
Oppenheimer
Oppenheimer
Price Target
$30 -> $35
2025-11-11
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Guardian Pharmacy to $35 from $30 and keeps an Outperform rating on the shares following quarterly results. Overall, the results were solid, as Guardian continues a methodical approach to growth that unlocks attractive value over time, the firm says.
Truist
David MacDonald
Buy
maintain
$28 -> $30
2025-09-26
Reason
Truist
David MacDonald
Price Target
$28 -> $30
2025-09-26
maintain
Buy
Reason
Truist analyst David MacDonald raised the firm's price target on Guardian Pharmacy to $30 from $28 and keeps a Buy rating on the shares. The firm remain bullish on Guardian post management meetings highlighting the company's strong positioning in a market with brisk core demand, overarching tailwinds and ongoing expansion opportunity, the analyst tells investors in a research note. Truist adds that Guardian's core trends remain strong, and the firm sees an attractive earnings power opportunity from recently acquired facilities.
Truist
Buy
maintain
$25 -> $28
2025-05-19
Reason
Truist
Price Target
$25 -> $28
2025-05-19
maintain
Buy
Reason
Raymond James
John Ransom
Outperform
maintain
$25 -> $28
2025-05-14
Reason
Raymond James
John Ransom
Price Target
$25 -> $28
2025-05-14
maintain
Outperform
Reason
Raymond James analyst John Ransom raised the firm's price target on Guardian Pharmacy to $28 from $25 and keeps an Outperform rating on the shares. The company's Q1 results were ahead of the firm's model on revenue, but $600,000 below on EBITDA due to some pull-forward on Heartland integration costs and a slight miss on seasonality, the analyst tells investors in a research note. This was a solid quarter with no major surprises outside of the small seasonality change, and Raymond James continues to like Guardian for its solid organic and inorganic growth potential, clean balance sheet with dry powder for M&A, and performance of operational execution.
Truist Securities
David Macdonald
Strong Buy
Maintains
$24 → $25
2025-04-11
Reason
Truist Securities
David Macdonald
Price Target
$24 → $25
2025-04-11
Maintains
Strong Buy
Reason
Truist analyst David MacDonald raised the firm's price target on Guardian Pharmacy to $25 from $24 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Guardian Pharmacy Services Inc (GRDN.N) is 28.26, compared to its 5-year average forward P/E of 24.67. For a more detailed relative valuation and DCF analysis to assess Guardian Pharmacy Services Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
24.67
Current PE
28.26
Overvalued PE
27.44
Undervalued PE
21.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
14.99
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.49
Undervalued EV/EBITDA
13.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.06
Current PS
0.00
Overvalued PS
1.19
Undervalued PS
0.94
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GRDN News & Events

Events Timeline

(ET)
2025-11-10
16:14:59
Guardian Pharmacy increases FY25 adjusted EBITDA forecast to $104M-$106M, up from $100M-$102M
select
2025-11-10
16:13:52
Guardian Pharmacy announces Q3 earnings per share, in line with consensus of 23 cents.
select
2025-10-14 (ET)
2025-10-14
16:50:42
Guardian Pharmacy submits Form S-3 and lock-up agreements with pre-IPO investors.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
10-29NASDAQ.COM
GRDN Surpasses Average Analyst Expectations

  • Stock Performance: Guardian Pharmacy Services Inc (GRDN) shares have surpassed the average analyst 12-month target price of $29.33, currently trading at $29.56/share.

  • Analyst Reactions: Analysts may respond to the stock reaching the target price by either downgrading their valuation or raising their target price, depending on the company's fundamental developments.

  • Diverse Analyst Targets: Within the Zacks coverage universe, there are varying analyst targets for GRDN, ranging from a low of $28.00 to a high of $30.00, with an average target reflecting a collective assessment.

  • Investor Considerations: The crossing of the average target price signals investors to evaluate whether GRDN's valuation is still attractive or if it’s time to consider selling some shares.

[object Object]
Preview
4.0
09-27NASDAQ.COM
Truist Securities Upholds Buy Rating for Guardian Pharmacy Services (GRDN)

  • Truist Securities Recommendation: Truist Securities has maintained a Buy recommendation for Guardian Pharmacy Services (NYSE:GRDN) as of September 26, 2025, with an average one-year price target of $27.88/share, indicating a potential upside of 7.17% from its current price of $26.02/share.

  • Institutional Ownership Trends: There has been a significant increase in institutional ownership of Guardian Pharmacy Services, with 237 funds reporting positions, a 30.94% increase in the last quarter, and total shares owned by institutions rising by 64.52% to 23,105K shares.

[object Object]
Preview
4.0
09-26Benzinga
Truist Securities Reaffirms Buy Rating for Guardian Pharmacy Service and Increases Price Target to $30

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Guardian Pharmacy Services Inc (GRDN) stock price today?

The current price of GRDN is 29.32 USD — it has increased 0.21 % in the last trading day.

arrow icon

What is Guardian Pharmacy Services Inc (GRDN)'s business?

Guardian Pharmacy Services, Inc. is a long-term care pharmacy services company. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.

arrow icon

What is the price predicton of GRDN Stock?

Wall Street analysts forecast GRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDN is 34.50 USD with a low forecast of 34.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Guardian Pharmacy Services Inc (GRDN)'s revenue for the last quarter?

Guardian Pharmacy Services Inc revenue for the last quarter amounts to 377.43M USD, increased 20.05 % YoY.

arrow icon

What is Guardian Pharmacy Services Inc (GRDN)'s earnings per share (EPS) for the last quarter?

Guardian Pharmacy Services Inc. EPS for the last quarter amounts to 0.16 USD, decreased -108.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Guardian Pharmacy Services Inc (GRDN)'s fundamentals?

The market is revising Upward the revenue expectations for Guardian Pharmacy Services, Inc. (GRDN) for FY2025, with the revenue forecasts being adjusted by 2.85% over the past three months. During the same period, the stock price has changed by 3.93%.
arrow icon

How many employees does Guardian Pharmacy Services Inc (GRDN). have?

Guardian Pharmacy Services Inc (GRDN) has 3400 emplpoyees as of December 05 2025.

arrow icon

What is Guardian Pharmacy Services Inc (GRDN) market cap?

Today GRDN has the market capitalization of 1.86B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free